for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alimera Sciences Inc

ALIM.OQ

Latest Trade

4.75USD

Change

0.18(+3.83%)

Volume

15,245

Today's Range

4.52

 - 

5.19

52 Week Range

0.00

 - 

18.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.58
Open
4.58
Volume
15,245
3M AVG Volume
0.90
Today's High
5.19
Today's Low
4.52
52 Week High
18.00
52 Week Low
0.00
Shares Out (MIL)
74.45
Market Cap (MIL)
23.58
Forward P/E
-25.82
Dividend (Yield %)
--

Next Event

Q4 2019 Alimera Sciences Inc Earnings Release

Latest Developments

More

Alimera Sciences Reports Q3 Loss Per Share Of $0.04

Alimera Sciences Inc Enters Purchase Agreement With Lincoln Park Capital Fund To Purchase Up To $20.0 Million Of Shares Of Co's Common Stock

Alimera Sciences Announces Top Line Revenue Expectation For The Third Quarter Of 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alimera Sciences Inc

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through U.S. and International segment. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, Canada, Lebanon and the United Arab Emirates, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Industry

Biotechnology & Drugs

Contact Info

6120 Windward Pkwy Ste 290

+1.678.9905740

http://www.alimerasciences.com/

Executive Leadership

C. Daniel Myers

Non-Executive Chairman of the Board

Richard S. Eiswirth

President, Chief Executive Officer

Phil Jones

Chief Financial Officer

David R. Holland

Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets

Philip Ashman

Senior Vice President, European Managing Director

Key Stats

2.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

-9.450

2017

-4.950

2018

3.750

2019(E)

-0.184
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.46
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-32.08
Return on Equity (TTM)
-24.89

Latest News

Latest News

BRIEF-Alimera Sciences Posts Q1 Loss Per Share Of $0.11

* Q1 REVENUE ROSE 48 PERCENT TO $9.8 MILLION Source text: (https://bit.ly/2KyoIEn) Further company coverage:

BRIEF-Alimera Sciences Enters Into $40 Mln Term Loan Agreement With Solar Capital

* ALIMERA SCIENCES INC- ENTERED INTO A $40 MILLION TERM LOAN AGREEMENT WITH SOLAR CAPITAL LTD

BRIEF-Alimera Sciences Inc reports qtrly loss per share ‍$0.08​

* Alimera Sciences Inc reports third quarter 2017 financial results

BRIEF-Alimera Sciences files for mixed shelf of up to $100 mln

* Alimera Sciences Inc files for mixed shelf of up to $100 million – SEC filing Source text - (http://bit.ly/2yCWftF) Further company coverage:

BRIEF-Alimera Sciences ‍announces Iluvien now available in Ireland​

* Alimera Sciences Inc - Announces Iluvien now available in Ireland Source text for Eikon: Further company coverage:

BRIEF-Alimera Sciences signs agreement for distribution of Iluvien in France

* Alimera Sciences signs agreement for exclusive distributor of Iluvien in France

BRIEF-Alimera Sciences Q2 ‍net loss per share $0.04​

* Alimera Sciences reports second quarter 2017 financial results

BRIEF-Alimera Sciences announces real-world audit data supporting positive benefits of iluvien treatment

* Alimera Sciences announces real-world audit data supporting the positive benefits of iluvien treatment

BRIEF-Alimera Sciences announces italian patients now being treated with Iluvien

* Alimera Sciences announces italian patients now being treated with Iluvien® Source text for Eikon: Further company coverage:

BRIEF-pSivida- in connection with new collaboration agreement, Alimera forgave $10 mln of co's share of losses associated with commercialization of ILUVIEN

* pSivida - in connection with new collaboration agreement, alimera forgave $10 million of co's share of losses associated with commercialization of ILUVIEN

BRIEF-ALIMERA SCIENCES REPORTS Q1 LOSS PER SHARE $0.10

* ALIMERA SCIENCES REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS

BRIEF-Alimera Sciences signs agreement for exclusive distributor of Iluvien in Spain

* Alimera Sciences signs agreement for exclusive distributor of Iluvien in Spain

BRIEF-Alimera Sciences Q4 adjusted non-gaap loss per share $0.10

* Alimera sciences reports record fourth quarter and full year 2016 financial results

BRIEF-Alimera Sciences and Knight Therapeutics file new drug submission for iluvien in Canada

* Alimera Sciences and Knight Therapeutics announce filing of new drug submission for iluvien in Canada

BRIEF-Alimera Sciences says its unit Alimera Sciences Ltd received pricing, reimbursement decree for ILUVIEN on Jan. 11

* Alimera Sciences-unit Alimera Sciences received pricing and reimbursement decree for ILUVIEN from Agenzia Italiana Del Farmaco (AIFA) on Jan 11, 2017 Source text for Eikon: Further company coverage:

BRIEF-Stonepine Capital LP reports 5.4 pct passive stake in Alimera Sciences

* Stonepine Capital LP reports 5.4 percent passive stake in Alimera Sciences Inc as of Nov 7 - sec filing Source text : http://bit.ly/2eKIZdy Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up